Victory Capital Management
PVLA

Victory Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Victory Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
11,403
-2,721
-19% -$284K ﹤0.01% 1706
2025
Q4 		$1.48M Buy
+14,124
New +$1.2M ﹤0.01% 1659
2020
Q2 		– Sell
-224
Closed -$40K – 3341
2020
Q1 		$40K Buy
+224
New +$56.4K ﹤0.01% 2861
2019
Q4 		– Sell
-93
Closed -$25K – 3330
2019
Q3 		$25K Buy
+93
New +$36K ﹤0.01% 2967

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management's PVLA Position: Q1 2026 in Review

Victory Capital Management reduced its Palvella Therapeutics (PVLA) stake by 19% in Q1 2026, selling an estimated $284K and leaving 11,403 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Victory Capital Management first reported a position in PVLA in Q3 2019 and has held it in 4 quarters since. The position peaked at $1.48M in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Victory Capital Management held 11,403 shares of Palvella Therapeutics worth $1.42M as of Q1 2026.
  • Victory Capital Management sold 2,721 Palvella Therapeutics shares in Q1 2026, an estimated $284K.
  • Palvella Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1706 holding.
  • Victory Capital Management first reported a position in Palvella Therapeutics in Q3 2019 and has held it in 4 quarters since.
  • Victory Capital Management's Palvella Therapeutics position peaked at $1.48M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.